Global Embolization Particle Market Research Report - Forecast to 2023

The market for embolization particle is expected to reach around USD 1,909.76 million by 2023 from USD 899.41 million in 2016 with a CAGR of 9.64% during the forecast period.

Reference: 180151
Price: $4,450.00
Tax included

General

Geography Covered
Global
Publisher:
Market Research Future
Publication Date
2017/12/25
Pages
113
Language
  • English
Format
License

Embolization particles are small and irregular flakes of polyvinyl alcohol, which are used for permanent occlusion within a blood vessel. The market is majorly driven by the growing demand of embolization particles for interventional radiology and interventional cardiovascular procedure, minimally invasive alternatives available for the interventional procedures. However, less number of interventional neuroradiologists and interventional neuroradiology (INR) labs, lack of skilled healthcare professionals in developing regions is expected to restrain the growth of this market.
The market for embolization particle is expected to reach around USD 1,909.76 million by 2023 from USD 899.41 million in 2016 with a CAGR of 9.64% during the forecast period.
On the basis of the product type the embolization particle market is segmented into radio-embolization and drug eluting beads. Radio-embolization accounts the largest market share in 2016. Radio-embolization segment is expected to reach USD 1,909.76 million by 2023 from USD 899.41 million in 2016.
The global embolization particle market on the basis of applications is segmented into oncology, urology, peripheral vascular disease, neurology, and others. The oncology segment accounts for the largest market share with USD 654.24 million of the global embolization particle market by applications followed by peripheral cardiovascular disease.
On the basis of end users hospitals & clinics accounts for the largest market share in 2016. The market is expected to reach USD 1,909.76 million by 2023 and is projected to grow at a CAGR of 11.33% during the forecast period.
On the basis of region the market is segmented into Americas, Europe, Asia-Pacific and Middle East and Africa. Asia-pacific region has projected to be the fastest growing at a CAGR of 10.11% during the forecast period from 2017-2023 due rising number of cancer patient base for the interventional oncology procedures in the region.
Key Players
Boston Scientific Corporation, Guerbet, BTG International Ltd, Medtronics, Sirtex, Terumo, Merit Medical are the major players of the global embolization particle market.
Study objectives
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of the market segments based on product type, application, level of occlusion, end user and regions for the global embolization particle market
• To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economical factors that influences the global embolization particle market
• To provide detailed analysis of the value chain and supply chain of the global embolization particle market
Target Audience
• Pharmaceutical and Biotech Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies
Key Findings
• The key players which provide affordable and effective treatments includes BTG, Guerbet, Boston Scientific, Sirtex, Terumo Corporation, and Merit Medical, and Medtronics among others and together holds around 70-75% of market share
• On the basis of level of occlusion, proximal segment accounts for largest market share compared to distal level of occlusion
• Currently, radioembolization microspheres are the most preferred product type due to for improved success rate and increase ease of use in the procedures
• The market is growing with an equitable pace of 8-9% annually. Growing advances in microspheres technologies, use of embolization particles as minimally invasive alternative to traditional treatments for interventional as well as PV embolization procedures has up surged the growth of the market
The reports also covers regional analysis
• Americas
o U.S.
o Canada
o South America
• Europe
o Germany
o France
o U.K
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Australia
o Rest of Asia-Pacific
o The Middle East & Africa

Table of Contents

1 Report Prologue 11
2 Market Introduction 15
2.1 Definition 15
2.2 Scope of the Study 15
2.2.1 Research Objective 15
2.2.2 Assumptions 15
2.2.3 Limitations 15
3 Research Methodology 17
3.1 Primary Research Methodology 18
3.2 Secondary Research Methodology 19
3.3 Market Size Estimation 20
3.4 Market Share Analysis 22
3.5 Trade Analysis 22
3.6 Market Pricing Approach 22
4 Market Dynamics 23
4.1 Introduction 23
4.2 Driver 24
4.2.1 Growing demand of embolization particles for interventional radiology and interventional cardiovascular procedure (Impact Weightage- 35%) 24
4.2.2 Embolization is best minimally invasive alternatives available for the interventional procedures (Impact Weightage- 30%) 25
4.2.3 Increasing prevalence of various types of cancer is one of the major factor responsible for market growth (Impact Weightage- 25%) 26
4.2.4 Favorable reimbursement scenario (Impact Weightage- 10%) 27
4.3 Restraints 28
4.3.1 Less number of interventional neuroradiologists and interventional neuroradiology (INR) labs (Impact Weightage- 40%) 28
4.3.2 Strict Regulatory Rules (Impact weightage-60% 29
4.4 Opportunities 30
4.4.1 Recent advances in microsphere technologies 30
4.5 Mega Trends 30
4.6 Macroeconomic indicators 31
5 Market Factor Analysis 32
5.1 Porter's Five Forces Analysis 32
5.1.1 Bargaining Power of Suppliers 33
5.1.2 Bargaining Power of Buyers 33
5.1.3 Threat of New Entrants 33
5.1.4 Threat of Substitutes 33
5.1.5 Intensity of Rivalry 33
5.2 Value Chain Analysis 34
5.2.1 R&D 34
5.2.2 Clinical Test & Legal Issues 35
5.2.3 Manufacturing 35
5.2.4 Marketing & Sales 35
5.3 Purchasing activities, Strategies and implications 36
5.4 Investment Opportunity Analysis 36
5.5 Pricing Impact of Embolization Particle (Lipiodol): Effects & Implications 37
5.6 Reimbursement issues in embolization procedures 39
6 Global Embolization Particle Market, By Product Type 40
6.1 Introduction 40
6.2 Radioembolization Spheres 41
6.3 Drug eluting Beads 42
7 Global Embolization Particle Market, By Application 43
7.1 Introduction 43
7.2 Oncology 45
7.3 Urology 46
7.4 Peripheral Vascular Disease 47
7.5 Neurology 48
8 Global Embolization Particle Market, By Level of Occlusion 49
8.1 Introduction 49
8.2 Proximal 50
8.3 Distal 50
9 Global Embolization Particle Market, By End User 51
9.1 Introduction 51
9.2 Hospitals & Clinics 52
9.3 Ambulatory Centers 52
10 Global Embolization Particle Market, By Region 53
10.1 Introduction 53
10.2 Americas 55
10.2.1 North America 58
10.2.1.1 U.S. 58
10.2.1.2 Canada 60
10.2.2 South America 62

10.3 Europe 65
10.3.1 Germany 68
10.3.2 France 70
10.3.3 UK 72
10.3.4 Italy 74
10.3.5 Spain 76
10.3.6 Rest of Europe 78
10.4 Asia Pacific 81
10.4.1 Japan 84
10.4.2 China 86
10.4.3 India 88
10.4.4 Republic of Korea 90
10.4.5 Australia 92
10.4.6 Rest of Asia Pacific 95
10.5 Middle East & Africa 98
11 Competitive Landscape 101
11.1 Introduction 101
11.2 Company Share Analysis 103
12 Company Profiles 104
12.1 Boston Scientific Corporation 104
12.1.1 Company Overview 104
12.1.2 Financials 104
12.1.3 Products 104
12.1.4 Strategy 104
12.1.5 Key Developments 104
12.2 Guerbet 105
12.2.1 Company Overview 105
12.2.2 Financials 105
12.2.3 Products 105
12.2.4 Strategy 105
12.2.5 Key Developments 105
12.3 BTG International Ltd 106
12.3.1 Company Overview 106
12.3.2 Financials 106
12.3.3 Products 106
12.3.4 Strategy 106
12.3.5 Key Developments 106
12.4 Medtronics 107
12.4.1 Company Overview 107
12.4.2 Financials 107
12.4.3 Products 107
12.4.4 Strategy 107
12.4.5 Key Developments 107
12.5 Sirtex 108
12.5.1 Company Overview 108
12.5.2 Financials 108
12.5.3 Products 108
12.5.4 Strategy 108
12.5.5 Key Developments 108
12.6 Terumo 109
12.6.1 Company Overview 109
12.6.2 Financials 109
12.6.3 Products 109
12.6.4 Strategy 109
12.6.5 Key Developments 109
12.7 Merit Medical 110
12.7.1 Company Overview 110
12.7.2 Financials 110
12.7.3 Products 110
12.7.4 Strategy 110
12.7.5 Key Developments 110
13 MRFR Conclusion 111
13.1 Key Findings 111
13.1.1 From CEO’s View Point 111
13.1.2 Unmet Needs 111
13.2 Key companies to watch 111
14 Appendix 112
14.1 Discussion Blue Print 112
14.2 References 114

Scroll